Romosozumab, a monoclonal antibody against sclerostin, was developed as an anabolic osteoporosis treatment following the discovery that loss-of-function mutations in the SOST gene, which produces sclerostin, underlies the rare high bone mass disorder sclerosteosis39. Here, SOST is linked to high bone mass osteogenesis imperfecta.